Hello everyone Josh here again. I’m sure by now you’ve already heard mumblings of Covid’s imminent return. We are seeing everything from colleges to hospitals start to implement Covid policies. The news cycle is starting to warn of a dangerous flu season/Covid return. Governments around the world are now updating their Covid policies and sleepy Joe’s White House...
Are you searching for a lucrative investment opportunity that promises great returns in 2023? Look no further as we unveil the hidden potential of Pfizer Pharmaceutical stock. In this blog post, we will delve into the compelling reasons why investing in Pfizer is not only a smart move but also an incredibly exciting. From groundbreaking innovations to robust...
Pfizer is one of the world’s leading pharmaceutical company specializes in vaccines, hospitals, internal medicines and inflammation and immunology. Their manufacturing capacity is 4 billion tablets annually and supplied in neighboring countries of India. Pfizer CMP is 3866. Negative aspects of the company are high valuation (P.E. = 28.3), MFs are decreasing...
Pfizer - Medium Term - We look to Sell at 39.88 (stop at 41.08) Bespoke resistance is located at 40. 40.14 has been pivotal. 40.37 has been pivotal. Daily signals are bearish. We look for a temporary move higher. Our profit targets will be 37.08 and 36.58 Resistance: 37.05 / 38.30 / 39.00 Support: 36.03 / 35.50 / 35.00 Please be advised that the...
Buy above high of breakout candle at 3851.4 stoploss at 3737.85
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under...
Over the past year, investors have been disappointed with Pfizer as the company's stock experienced a significant decline of 28.8%. This decline can be attributed, in part, to the anticipated drop in sales for Pfizer's COVID-19 vaccine, Comirnaty, and its antiviral treatment, Paxlovid. However, there is an overlooked aspect that investors have failed to recognize:...
They're buying Seagen for $43 billion so they can build an anti-cancer franchise. They need this. Pfizer has a strong pipeline, but when will they get behind their migraine drug, which was part of an acquisition? They're doing nothing with it.
When I began research for this post I expected to be giving the bull case for Pfizer. It's the type of stock I like - a household name oozing with quality and prestige, a strong moat, beaten up with strongly bearish sentiment with multiple factors pointing towards recovery, with short term technical support and long term positive fundamental outlook. I like to...
This is a make or break moment for NYSE:PFE Close this and next week below we sell and look for that next level. But we should be seeing a short squeeze "soon"(1-2 weeks).
NYSE:PFE Pfizer Inc. (PFE) is a leading pharmaceutical company with a diverse portfolio of drugs and products, including vaccines, oncology, and rare disease treatments. The successful rollout of COVID-19 vaccines has been a significant driver of Pfizer's revenue growth, with revenue increasing from HKEX:41 billion in 2020 to HKEX:81 billion in 2021 and...
The price has been traded in a downnsloping channel . We expect the bounce from the donwsloping support. Spelucative long position: entry: 38,43 target: 47,82 stop loss: 37,49
pfizer is gonna make wave c for target TASE:49 at least and HKEX:52
The PFE stock, Pfizer, Inc., looks like is about to take a deep dive... Going red... Let's have a look! The most obvious signal is the weekly candle today moving below EMA50, telling us that this stock is preparing to drop for months. Pfizer, Inc. peaked December 2021. In mid-December 2022 PFE printed the inverted hammer bearish candlestick pattern or shooting...
You may be familiar with the negative sentiment surrounding Pfizer, with many citing the company's heavy reliance on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid as a cause for concern. In addition to this, several of Pfizer's top-selling drugs will face patent expirations in the near future, leading many to believe that the company's stock will...
Buy Feb-24-23 43.5 Calls @ 0.1 Limit to Open (Weekly) Buy Mar-24-23 47 Calls @ 0.11 Limit to Open (Monthly (W))
6M Chart, PFE , on February 6, 2023, the signals on MACD have been steadily moving NE, after piercing below the histogram on July 2012; On July 2021, reached its ATH (All Time High); The RSI signal bounced over 70 and is now facing SE to test the line of 50, after bouncing up from it on January 2020; The price has been steadily falling since the ATH, from $60 to...
#Pfizer has been oversold for some time. Today's gap down on UBS downgrade could be the seller exhaustion and potential bounce to come. Target 1 - $46.5 Target 2 - $47.67 Target 3 - $51 Long term - $60 Risk - fall to $41. —— Trade is done when it hit one of the target or stop loss is hit. Disclaimer: Trading note. Not an investment advice.